Every day, thousands of hospitals, ambulatory surgery centers, cancer clinics, and emergency departments across the United States depend on medications that are not manufactured by traditional pharmaceutical companies.
Instead, many of these life-saving sterile drugs come from FDA-registered 503B outsourcing facilities; specialized compounding pharmacies created under the Drug Quality and Security Act (DQSA) after the 2012 fungal meningitis outbreak to strengthen patient safety and improve drug quality.
Source: U.S. 503B Compounding Pharmacies Market
Unlike traditional 503A pharmacies, which prepare medicines for individual prescriptions, 503B outsourcing facilities can produce sterile medications in larger quantities for healthcare providers without patient-specific prescriptions.
These facilities must register with the FDA, follow Current Good Manufacturing Practices (cGMP), undergo risk-based FDA inspections, report compounded products twice each year, and comply with adverse event reporting requirements.
As of June 23, 2026, the FDA lists around 90 active registered 503B outsourcing facilities operating across the United States.
While the facilities are spread across multiple regions, nearly half are concentrated in only a handful of states, creating major pharmaceutical manufacturing hubs.
Why Are Certain States Leading the 503B Industry?
The answer is surprisingly simple.
States with strong pharmaceutical manufacturing ecosystems, skilled healthcare workforces, favorable logistics, and access to major hospital networks have naturally attracted more outsourcing facilities.
Texas and Florida have emerged as national leaders because they combine large healthcare markets with extensive pharmaceutical infrastructure.
New Jersey follows closely due to its long-standing pharmaceutical industry presence, while California continues expanding with biotechnology-driven investments.
503B Outsourcing Facilities by Leading States
| State | Approx. Registered 503B Facilities | Examples |
|---|---|---|
| Texas | 15 | Empower Pharmacy, QuVa Pharma, Wells Pharma, AH Nutraceutical Compounding |
| Florida | 15 | Olympia Pharmaceuticals, PQ Pharmacy, Rapha Pharmaceuticals |
| New Jersey | 9 | QuVa Pharma (NJ), Epicur Pharma, Hikma facilities |
| California | 5 | McGuff Outsourcing Solutions, MediSourceRx |
| Arizona/Nevada Region | 4 | AnazaoHealth and regional outsourcing facilities |
| Pennsylvania | 3+ | ProRx, PGRrx |
| Oklahoma | 2 | Qualgen LLC, Quantum Pharmaceuticals |
| Ohio | 2 | RC Outsourcing LLC and others |
| New York | 2 | Pine Pharmaceuticals and others |
Texas: America’s Largest 503B Manufacturing Hub
Texas has become the country’s largest concentration of 503B outsourcing facilities.
Houston alone has evolved into a major center for sterile compounding, supplying hospitals, surgery centers, pain management clinics, and physician offices throughout the United States.
Companies such as Empower Pharmacy, QuVa Pharma, Wells Pharma, and AH Nutraceutical Compounding have significantly expanded production capacity over the past decade.
Several Texas-based facilities now distribute sterile injectable medications nationwide.
Florida Continues Rapid Expansion
Florida now matches Texas with roughly 15 FDA-registered facilities.
Companies including Olympia Pharmaceuticals, PQ Pharmacy, Rapha Pharmaceuticals, and several newly registered outsourcing facilities have strengthened the state’s role in supplying compounded sterile medications.
Its growing biotechnology sector and expanding healthcare infrastructure continue attracting new investments.
New Jersey Remains a Pharmaceutical Powerhouse
New Jersey’s decades-long pharmaceutical heritage has naturally extended into the 503B market.
Companies including QuVa Pharma, Epicur Pharma, and other outsourcing facilities benefit from proximity to major pharmaceutical companies, research organizations, and healthcare systems.
The state’s skilled workforce continues supporting high-quality sterile manufacturing operations.
California’s Growth Is Driven by Biotechnology
California may have fewer registered facilities than Texas or Florida, but its outsourcing pharmacies serve one of the nation’s largest healthcare markets.
Biotechnology innovation, academic medical centers, and specialty hospitals continue driving demand for sterile compounded medications throughout the state.
The market is expected to continue expanding alongside California’s life sciences ecosystem.
The FDA’s Oversight Continues to Grow
Registration alone does not guarantee compliance.
FDA inspectors routinely conduct risk-based inspections and may issue Form 483 observations, warning letters, recalls, or additional regulatory actions whenever manufacturing deficiencies are identified.
Facilities must also renew registration annually to remain on the FDA’s official outsourcing facility list.
Why 503B Facilities Matter More Than Ever
Drug shortages continue affecting hospitals across the United States, particularly for injectable medications, anesthesia products, oncology drugs, and emergency medicines.
During shortages, many hospitals rely on FDA-registered 503B outsourcing facilities to maintain continuity of patient care while meeting strict manufacturing requirements.
This role has made outsourcing facilities an increasingly important component of the U.S. pharmaceutical supply chain.
Although the U.S. has tens of thousands of retail pharmacies, only about 90 FDA-registered 503B outsourcing facilities currently operate nationwide.
This small but highly specialized industry supports hospitals, surgery centers, physician offices, and healthcare systems by producing high-quality sterile compounded medications under FDA oversight.
With healthcare demand increasing, hospital networks expanding, and persistent drug shortages continuing to challenge the pharmaceutical supply chain, states such as Texas, Florida, New Jersey, and California are expected to remain the primary centers of 503B outsourcing growth in the years ahead.
Access our exclusive, data-rich dashboard dedicated to the pharma industry – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
About Us
Healthcare WebWire is a part of Towards Healthcare Research and Consulting provides strategic intelligence and research expertise across the pharmaceutical market, including branded drugs, generic medicines, biologics, biosimilars, specialty pharmaceuticals, OTC products, and drug delivery systems. We support pharmaceutical companies with market analysis, pipeline assessment, and competitive insights to help drive innovation, strengthen commercialization strategies, and capture emerging growth opportunities in the evolving healthcare landscape.
You can place an order or ask any questions, please feel free to contact us at [email protected]
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium